Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.75
Bid: 2.60
Ask: 2.90
Change: 0.00 (0.00%)
Spread: 0.30 (11.538%)
Open: 2.75
High: 2.75
Low: 2.75
Prev. Close: 2.75
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

Wed, 13th Dec 2023 21:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

British Smaller Cos VCT PLC and VCT 2 - Leeds, England-based venture capital trusts - Confirm the addition of an over-allotment facility of GBP25 million to their subscription offer, following its launch in September. Add that they have received applications approaching GBP60 million so far, with the deadline for applications on March 28, 2024. Notes subscription was initially launched to raise GBP65 million.

----------

Frontier IP Group PLC - London-based intellectual property commercialisation company - Says portfolio company The Vaccine Group has appointed three animal health experts to its advisory board in order to support the scale-up of its herpesvirus-based platform. Says advisory board members are Merck & Co Inc's Christophe Barnier-Quer, as well as Johan Dreesen and Vaughn Kubiak. Neil Crabb, Frontier IP Chief Executive Officer, says: "I am delighted TVG has been able to form an advisory group of such good quality. It is a testament to the potential of the Company, its vaccine platform and pipeline, and I look forward to further developments as TVG's vaccines move towards scale up and full commercialisation."

----------

DeepVerge PLC - Dublin-based environmental and life sciences firm - Says it has made progress in its discussions with potential buyers of assets and intellectual property in its Modern Water and Labskin business units. Adds that it hopes to agree on a sale in January. Says, however, that even if both asset sets are sold, the sales will not be of enough value to avoid closure or administration of the two subsidiaries. Adds that it currently has debts of GBP300,000 and is unsure whether it will have the funds to pay these debts. Says shares expected to be cancelled on December 27.

----------

Good Energy Group PLC - Wiltshire, England-based supplier of 100% renewable power and an innovator in energy services - Says investee company Zapmap, an electric vehicle charge point mapping service, has expanded its market presence to mainland Europe. Says its mapping service is now available in France, Germany, Belgium, the Netherlands and Luxembourg. Says coming months will see Zapmap open features including EV route planning and charging payments. Good Energy Chief Executive Nigel Pocklington says: "Zapmap has made significant progress over the last year as it continues to broaden and deepen its market presence in the UK and now across Europe. It continues to track with the rapidly growing electric vehicle market, which has expanded by 40% in the UK last year with the share of electric vehicles new car registrations increasing in almost all EU countries."

----------

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Launches placing to raise GBP1.6 million, via the issue of 26.3 million shares at 6.0 pence each. Adds that it will also launch a retail offer at 6.0 pence per retail share. Says retail offer is only open to existing shareholders. Notes that certain directors will also subscribe for 500,000 shares at 6.0p each. Says it will raise GBP1.9 million in total, which will be used to integrate BioBank materials form its asset acquisition from Imagen, as well as research and development.

----------

Creo Medical Group PLC - Chepstow, Wales-based medical device company - Says it has completed the first procedure using Speedboat Ultraslim. Says the product was used for a lower Gastrointestinal tract procedure in the UK, with the first European procedure expected to follow shortly. Speedboat is used to treat gastrointestinal tract diseases, including bowel, stomach and oesophagus cancers. CEO Craig Gulliford comments: "This is yet another landmark moment for Creo Medical. We know what a difference this even smaller device will make in terms of broadening access to advanced energy in endoscopy for a wider pool of clinicians. Speedboat UltraSlim is compatible with all major endoscopes, meaning clinicians can bring advanced energy to their practices, allowing more patients to be treated endoscopically, which avoids surgery and the associated secondary costs and risks."

----------

Macfarlane Group PLC - Glasgow-based supplier of packaging materials - Promotes James Baird to senior independent director.

----------

Asia Strategic Holdings Ltd - Singapore-based developer and operator of consumer businesses located in emerging Asian economies - Agrees amended loan facility with Macan Pte Ltd, increasing its loan to USD4.5 million, from USD3.0 million. Adds that the increase is in order to support its expansion of its school network. Notes that it has agreed to extend the repayment date to December 31 2027. Macan is the largest shareholder of Asia Strategic, representing 32.4%, while Asia Strategic Chief Executive Enrico Cesenni holds 35.1% of the voting rights of Macan.

----------

By Harvey Dorset, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Nov 2013 10:28

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more
15 Nov 2013 07:53

AIM IN BRIEF: Quindell And ValiRx Placings; Noricum Gold Positive Results

Read more
24 Oct 2013 15:48

ValiRx Anti-Cancer Treatment Advances To Phase 2 Of Clinical Trial

Read more
3 Oct 2013 11:39

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

Read more
3 Oct 2013 08:08

ValiRx Cancer Treatment Files Escalation Study

Read more
5 Sep 2013 11:44

ValiRX reports encouraging progress despite losses

ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made "excellent" advances in its clinical and pre-clinical development pipeline. It reiterated that it expected results from the first stage of clinical trials for its

Read more
5 Sep 2013 09:20

ValiRx Losses Widen But Says Compounds Progressing In Trials

Read more
25 Apr 2013 10:02

ValiRx granted patent in Australia for VAL201 targeting cancer

ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia. The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormon

Read more
2 Apr 2013 08:41

ValiRx to present at key Cancer Conference

Shares in life science company ValiRx rose on Tuesday morning after the AIM-listed company announced that it would be presenting at the American Association for Cancer Research Conference this year. The conference, which was attended by approximately 17,000 delegates last year, is seen as a key eve

Read more
21 Feb 2013 13:17

ValiRx appoints COO to help build portfolio

Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy. Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identi

Read more
22 Nov 2012 15:56

Small cap round-up: InterQuest, ValiRx, Aeorema Comms

InterQuest has warned that trading during the summer, traditionally its strongest period, has been sluggish. As a result underlying earnings before interest, tax, depreciation and amortisation (EBITDA) will be in the region of 2.2m pounds. This does not include an exceptional credit of about 0.85m p

Read more
11 Oct 2012 09:50

Contract wins round-up: LO-Q, Motive TV, Plexus ...

Lo-Q has announced its second contract win of the week, as an unnamed major US theme park operator has signed up to use the firm's virtual queueing system at two sites in the US. Revenue associated with the agreement is expected to scale gradually, over time. In addition, the deal grants that Lo-Q's

Read more
29 May 2012 08:37

Small cap round-up: ValiRx, Transense, Sweett

Shares in ValiRx, the life sciences firm, leapt almost 40% on Tuesday after it said independent trials had confirmed the effectiveness of its prostate cancer drug VAL201. The firm said the "significant and substantively important findings" showed its drug reduced the spread of secondary tumours by u

Read more
15 May 2012 13:12

Small caps round-up: Cello, DDD, Kewill...

Marketing firm Cello Group has reported good trading during the first three months of the year, reflecting 'the strong pipeline of work secured at the end of 2011 and a solid flow of bookings'. The research and consulting division was a strong performer, while the group's focus on the pharmaceutic

Read more
27 Apr 2012 14:20

Small caps round-up: James Cropper, ValiRx, ReNeuron

James Cropper, a specialist paper and materials group, has said that pre-execptional profit before tax is set to be in line with market expectations. The company also said its previously announced restructuring process will reduce the size of the UK workforce by eight per cent during the current yea

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.